Back to discover

Protein / target

Interleukin-15

Encoded byIL15P40933Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Antibody-tractable
Druggability
Advanced Clinical
8
Research papers

Protein at a glance

Biological role

Cytokine receptor binding

Strongest disease association

Hypothyroidism

Via encoding gene IL15 · Genetic evidence · score 0.78

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

8 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems.

View complete UniProt function annotation

Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems (PubMed:15123770). Stimulates the proliferation of natural killer cells, T-cells and B-cells and promotes the secretion of several cytokines (PubMed:8178155, PubMed:9326248). In monocytes, induces the production of IL8 and monocyte chemotactic protein 1/CCL2, two chemokines that attract neutrophils and monocytes respectively to sites of infection (PubMed:9326248). Unlike most cytokines, which are secreted in soluble form, IL15 is expressed in association with its high affinity IL15RA on the surface of IL15-producing cells and delivers signals to target cells that express IL2RB and IL2RG receptor subunits (PubMed:10233906, PubMed:23104097, PubMed:8026467). Binding to its receptor triggers the phosphorylation of JAK1 and JAK3 and the recruitment and subsequent phosphorylation of signal transducer and activator of transcription-3/STAT3 and STAT5 (PubMed:7568001). In mast cells, induces the rapid tyrosine phosphorylation of STAT6 and thereby controls mast cell survival and release of cytokines such as IL4 (By similarity)

Subcellular location

SecretedCytoplasmNucleus
Domains and Gene Ontology detail (29)

Gene Ontology

  • Ccytoplasm
  • Cendosome
  • Cextracellular region
  • Cextracellular space
  • CGolgi apparatus
  • Cnuclear speck
  • Cnucleoplasm
  • Fcytokine activity
  • Fcytokine receptor binding
  • Pcell surface receptor signaling pathway via JAK-STAT
  • Pcell-cell signaling
  • Pimmune response

162 aa · 18 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalUniProt · GOImmune signallingGO
View supporting evidence

Cell proliferation & survival

  • ·Cytokine that plays a major role in the development of inflammatory and protective immun…
  • ·positive regulation of cell population proliferation

Immune signalling

  • ·cytokine activity
  • ·cytokine receptor binding
  • ·immune response
  • ·interleukin-15-mediated signaling pathway

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL15

Gene-level evidence surfaced through the gene IL15that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypothyroidism
0.78Well supported

Genetic evidence dominant · Open Targets 0.48

Smoking initiation
0.58Moderately supported

Genetic evidence dominant · Open Targets 0.35

Parasitic Diseases
0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Neuroendocrine Tumors
0.40Limited support

Genetic evidence dominant · Open Targets 0.24

Dermatitis, Atopic
0.39Limited support

Genetic evidence dominant · Open Targets 0.23

View evidence synthesis (5)
HypothyroidismWell supported
0.78
agreement 0.660.90
Genetic100%

Open Targets aggregate 0.48 · 1 independent evidence family

Smoking initiationModerately supported
0.58
agreement 0.460.70
Genetic100%

Open Targets aggregate 0.35 · 1 independent evidence family

Parasitic DiseasesLimited support
0.42
agreement 0.280.56
Genetic92%Literature8%

Open Targets aggregate 0.25 · 2 independent evidence families

Neuroendocrine TumorsLimited support
0.40
agreement 0.280.52
Genetic100%

Open Targets aggregate 0.24 · 1 independent evidence family

Dermatitis, AtopicLimited support
0.39
agreement 0.250.53
Genetic96%Literature4%

Open Targets aggregate 0.23 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypothyroidism0.48
Smoking initiation0.35
Parasitic Diseases0.25
Neuroendocrine Tumors0.24
Dermatitis, Atopic0.23
Brain Neoplasms0.19

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
ORDESEKIMABPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

AntibodiesStrong

Advanced Clinical and GO CC high conf support this modality.

Protein degradersEmerging

Feasibility evidence (small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
AB · Advanced ClinicalAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

8 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Dudley ME · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008

Europe PMC papers linked directly to this protein.